CA2605669A1 - Method for treating advanced ovarian cancer with doxorubicin entrapped in liposomes - Google Patents

Method for treating advanced ovarian cancer with doxorubicin entrapped in liposomes Download PDF

Info

Publication number
CA2605669A1
CA2605669A1 CA002605669A CA2605669A CA2605669A1 CA 2605669 A1 CA2605669 A1 CA 2605669A1 CA 002605669 A CA002605669 A CA 002605669A CA 2605669 A CA2605669 A CA 2605669A CA 2605669 A1 CA2605669 A1 CA 2605669A1
Authority
CA
Canada
Prior art keywords
administering
liposomes
ovarian cancer
patient
entrapped
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002605669A
Other languages
English (en)
French (fr)
Inventor
Ronald D. Alvarez
J. Michael Straughn, Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2605669A1 publication Critical patent/CA2605669A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA002605669A 2005-04-21 2006-04-20 Method for treating advanced ovarian cancer with doxorubicin entrapped in liposomes Abandoned CA2605669A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67418805P 2005-04-21 2005-04-21
US60/674,188 2005-04-21
PCT/US2006/015528 WO2006116341A1 (en) 2005-04-21 2006-04-20 Method for treating advanced ovarian cancer with doxorubicin entrapped in liposomes

Publications (1)

Publication Number Publication Date
CA2605669A1 true CA2605669A1 (en) 2006-11-02

Family

ID=36811891

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002605669A Abandoned CA2605669A1 (en) 2005-04-21 2006-04-20 Method for treating advanced ovarian cancer with doxorubicin entrapped in liposomes

Country Status (11)

Country Link
US (1) US20070026060A1 (enExample)
EP (1) EP1874324A1 (enExample)
JP (1) JP2008538584A (enExample)
KR (1) KR20080008367A (enExample)
CN (1) CN101163485A (enExample)
AU (1) AU2006238877A1 (enExample)
BR (1) BRPI0609939A2 (enExample)
CA (1) CA2605669A1 (enExample)
IL (1) IL186699A0 (enExample)
MX (1) MX2007013056A (enExample)
WO (1) WO2006116341A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2609216T3 (en) 2010-08-24 2016-09-12 Dana Farber Cancer Inst Inc Methods to predict anti-cancer response
EP3693473B1 (en) 2011-06-17 2025-02-19 Myriad Genetics, Inc. Methods and materials for assessing allelic imbalance
UY34295A (es) * 2011-09-08 2013-04-30 Servier Lab Nuevo esquema de administración de la n-hidroxi -4- {2-[3- (n,ndimetilaminometil)benzofuran -2- ilcarbonilamino]etoxi}benzamida
BR112014015152A2 (pt) 2011-12-21 2017-07-04 Myriad Genetics Inc métodos e materiais para a avaliação da perda de heterozigosidade
DK3415915T3 (da) 2012-02-23 2024-11-04 Childrens Medical Center Fremgangsmåde til at forudsige respons til PARP-inhibitorer
AU2013273466B2 (en) 2012-06-07 2018-11-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for detecting inactivation of the homologous recombination pathway (BRCA1/2) in human tumors
WO2014160080A1 (en) 2013-03-14 2014-10-02 Children's Medical Center Corporation Cancer diagnosis, treatment selection and treatment
WO2015086473A1 (en) 2013-12-09 2015-06-18 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
ES2946251T3 (es) 2014-08-15 2023-07-14 Myriad Genetics Inc Métodos y materiales para evaluar la deficiencia de recombinación homóloga

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6923966B2 (en) * 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
WO2001032145A1 (en) * 1999-10-29 2001-05-10 Board Of Regents, The University Of Texas System Method of cancer treatment

Also Published As

Publication number Publication date
MX2007013056A (es) 2008-04-07
CN101163485A (zh) 2008-04-16
AU2006238877A1 (en) 2006-11-02
JP2008538584A (ja) 2008-10-30
BRPI0609939A2 (pt) 2010-05-11
WO2006116341A1 (en) 2006-11-02
US20070026060A1 (en) 2007-02-01
KR20080008367A (ko) 2008-01-23
EP1874324A1 (en) 2008-01-09
IL186699A0 (en) 2008-02-09

Similar Documents

Publication Publication Date Title
Gandara et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non–small-cell lung cancer: phase II Southwest Oncology Group Study S9504
Fornasiero et al. Chemotherapy of invasive thymoma.
Sparano et al. Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer
Ayash et al. High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma.
Baas et al. Caelyx™ in malignant mesothelioma: A phase II EORTC study
Fleming et al. Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study
Howell et al. A phase II trial of intraperitoneal cisplatin and etoposide for primary treatment of ovarian epithelial cancer.
Yun et al. A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer
US20070026060A1 (en) Method for treating advanced ovarian cancer
Orditura et al. Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity
Rivera et al. Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer
Williams et al. Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study
De Lena et al. Revertant and potentiating activity of lonidamine in patients with ovarian cancer previously treated with platinum.
Aigner et al. Celiac axis infusion and microembolization for advanced stage III/IV pancreatic cancer-a phase II study on 265 cases
Laber et al. A phase I/II study of docetaxel in combination with pegylated liposomal doxorubicin in metastatic castration-resistant prostate cancer
WO2001083020A1 (en) Antineoplastic platinum therapeutic method and composition
EP1796689A1 (en) Free or liposomal gemcitabine alone or in combination with free or liposomal idarubicin
Recchia et al. A multicenter phase II study of pegylated liposomal doxorubicin and oxaliplatin in recurrent ovarian cancer
Veronesi et al. Cis-platinum and etoposide combination chemotherapy of advanced non-oat cell bronchogenic carcinoma
Schütte et al. 191 Phase II trial of paclitaxel and carboplatin as first line treatment in advanced non small cell lung-cancer (NSCLS)
Rosell et al. Cyclophosphamide and ifosfamide combination as neoadjuvant chemotherapy for locally advanced nonsmall‐cell lung cancer: A meta‐analytic review
Treat et al. Elliptinium: phase II study in advanced measurable breast cancer
Golden et al. Treatment of large solid tumors in mice with daunomycin-loaded sterically stabilized liposomes
Mougenot et al. In vitro cytotoxic effect of melphalan and pilot phase II study in hormone-refractory prostate cancer
Haddad et al. Phase II study of docetaxel and topotecan combination chemotherapy in patients with advanced head and neck cancer

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued